| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
183,678,000 |
| Market
Cap: |
4.50(B) |
| Last
Volume: |
775,760 |
Avg
Vol: |
773,615 |
| 52
Week Range: |
$23.37 - $33.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 581 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
35,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
15,666 |
15,666 |
48,238 |
146,962 |
| Total Sell Value |
$454,291 |
$454,291 |
$1,411,373 |
$4,368,837 |
| Total People Sold |
3 |
3 |
3 |
5 |
| Total Sell Transactions |
3 |
3 |
6 |
9 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wysenski Nancy |
Director |
• • – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,578 |
10,278 |
|
- |
|
| Wilson Frank Anders |
Director |
• • – |
2021-12-02 |
4 |
D |
$22.11 |
$29,605 |
D/D |
(1,339) |
8,939 |
|
- |
|
| Wilson Frank Anders |
Director |
• • – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,578 |
10,278 |
|
- |
|
| Dixon Wendy L |
Director |
• • – |
2021-12-02 |
4 |
D |
$22.11 |
$29,605 |
D/D |
(1,339) |
45,539 |
|
- |
|
| Dixon Wendy L |
Director |
• • – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,578 |
46,878 |
|
- |
|
| Cooke Shane |
Director |
• • – |
2021-12-02 |
4 |
D |
$22.11 |
$64,141 |
D/D |
(2,901) |
90,478 |
|
- |
|
| Cooke Shane |
Director |
• • – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,578 |
93,379 |
|
- |
|
| Snyderman Nancy Lynn Md |
Director |
• • – |
2021-12-02 |
4 |
D |
$22.11 |
$29,605 |
D/D |
(1,339) |
8,939 |
|
- |
|
| Snyderman Nancy Lynn Md |
Director |
• • – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,578 |
10,278 |
|
- |
|
| Anstice David W |
Director |
• • – |
2021-12-02 |
4 |
D |
$22.11 |
$29,605 |
D/D |
(1,339) |
77,320 |
|
- |
|
| Anstice David W |
Director |
• • – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,578 |
78,659 |
|
- |
|
| Gaynor Richard |
Director |
• • – |
2021-12-02 |
4 |
D |
$22.11 |
$29,605 |
D/D |
(1,339) |
8,939 |
|
- |
|
| Gaynor Richard |
Director |
• • – |
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,578 |
10,278 |
|
- |
|
| Jackson Blair Curtis |
EVP, Chief Operating Officer |
• • – |
2021-09-14 |
4 |
D |
$30.60 |
$61,934 |
D/D |
(2,024) |
73,014 |
|
- |
|
| Jackson Blair Curtis |
EVP, Chief Operating Officer |
• • – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,884 |
75,038 |
|
- |
|
| Brown Iain Michael |
SVP, Chief Financial Officer |
• • – |
2021-09-14 |
4 |
D |
$30.60 |
$93,544 |
D/D |
(3,057) |
46,807 |
|
- |
|
| Brown Iain Michael |
SVP, Chief Financial Officer |
• • – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,884 |
49,864 |
|
- |
|
| Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
• • – |
2021-09-14 |
4 |
D |
$30.60 |
$109,120 |
D/D |
(3,566) |
221,246 |
|
- |
|
| Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
• • – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
8,031 |
224,812 |
|
- |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2021-09-14 |
4 |
D |
$30.60 |
$141,800 |
D/D |
(4,634) |
80,518 |
|
- |
|
| Gaffin David Joseph |
SVP, CLO, Alkermes, Inc. |
• • – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,555 |
85,152 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2021-09-14 |
4 |
D |
$30.60 |
$141,005 |
D/D |
(4,608) |
18,538 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,672 |
23,146 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2021-09-14 |
4 |
D |
$30.60 |
$172,798 |
D/D |
(5,647) |
9,496 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2021-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,143 |
15,143 |
|
- |
|
1496 Records found
|
|
Page 12 of 60 |
|
|
0.22 (0.89%) 
